Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients

Transplantation

Volumn 90, Issue 12, 2010, Pages 1473-1477

  Reinsmoen, Nancy L ^a   Lai, Chih Hung ^a   Heidecke, Harald ^b   Haas, Mark ^a   Cao, Kai ^a   Ong, Geraldine ^a   Naim, Mehrnoush ^a   Wang, Qi ^a   Mirocha, James ^c   Kahwaji, Joseph ^a   Vo, Ashley A ^a   Jordan, Stanley C ^a   Dragun, Duska ^d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b CellTrend GmbH   (Germany)

^c Cardiothoracic Surgical Research Lab   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiangiotensin II type 1 receptor antibodies; Antibody mediated rejection; Donor HLA specific antibodies; Kidney transplantation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIGEN BINDING; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HLA SYSTEM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ACUTE DISEASE; ANTIBODIES; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CHROMOSOMES, HUMAN, PAIR 3; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RECEPTOR, ANGIOTENSIN, TYPE 1; TISSUE DONORS;

EID: 78650848684     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fd97f1     Document Type: Article

References (35)

1. Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific or endothelial cells. Tranpl Immunol 1997; 5: 321.
2. Sumitran-Holgersson S, Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268.
3. Zou Y, Heinemann FM, Grosse-Wilde H, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the posttransplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67: 230.
4. Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: Long-term follow-up after liver transplantation. Transplantation 2007; 83: 1126.
5. Aguilera I, Alvarez-Marquez A, Gentil MA, et al. Anti-glutathione Stransferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients. Nephrol Dial Transplant 2008; 23: 2393.
6. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86: 1019.
7. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal allograft rejection. N Engl J Med 2005; 352: 558.
8. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigenantibodies. Transplantation 2008; 85: 1557.
9. Rose ML. Role of MHC and non-MHC antibodies in graft rejection. Curr Opin Organ Transplant 2004; 9: 16.
10. Praprotnik S, Blank M, Meroni PL, et al. Classification of antiendothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells. Arthritis Rheum 2001; 44: 1484.
11. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886.
12. Carter V, Shenton BK, Jaques B, et al. Vimentin antibodies:Anon-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654.
13. Lawson C, Holder AL, Stanford RE, et al. Anti-intracellular adhesion molecule-1 antibodies in sera of heart transplant recipients: A role in endothelial activation. Transplantation 2005; 80: 264.
14. Hunyadi L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953.
15. Fu ML, Herlitz H, Schulze W, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000; 18: 945.
16. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945.
17. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047.
18. Dechend R, Viedt C, Muller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003; 107: 1632.
19. Miller JA, Scholey JW. The impact of renin-angiotensin polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens 2004; 13: 101.
20. Scornik JC, Guerra G, Schold JD, et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007; 7: 1808.
21. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 1.
22. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312.
23. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J f Transplant 2009; 9: 2561.
24. Slowinski T, Suker D, Schonemann C, et al. Screening of patients on waiting-list for a renal transplant for agonistic non-HLA antibodies targeting angiotensin II type 1 receptor (abstract). J Am Soc Nephrol 2006; 17: 393a.
25. Dragun D. The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediatr Nephrol 2007; 22: 911.
26. Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on-1-adrenergic receptors in patients with malignant hypertension. Lancet 1994; 344: 1660.
27. Coffman TM, Crowley SD. Kidney in hypertension guyton redux. Hypertension 2008; 51: 811.
28. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: Is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 2232.
29. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: When allo is not enough. Transplantation 2010; 90: 113.
30. Schwimmbeck PL, Dyrberg T, Drachman DB, et al. Molecular mimicry and myasthenia gravis: An autoantigenic site of the acetylcholine receptor-Subunit that has biologic activity and reacts immuno-chemically with herpes simplex virus. J Clin Invest 1989; 84: 1174.
31. Masuda MO, Levin M, De Oliveira SF, et al. Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 1998; 12: 1551.
32. Stepan H, Wallukat G, Schultheiss HP, et al. Is parvovirus B19 the cause for autoimmunity against angiotensin II type 1 receptor? J Reprod Immunol 2007; 73: 130.
33. Weidanz JA, Jacobson LM, Muehrer RJ, et al. ATR blockade reduces IFN-gamma production in lymphocytes in vivo and in vitro. Kidney Int 2005; 67: 2134.
34. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
35. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.